Comparative Pharmacology
Head-to-head clinical analysis: IGALMI versus LUMIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IGALMI versus LUMIFY.
IGALMI vs LUMIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the central nervous system, resulting in decreased agitation and sedation.
Selective alpha-1 adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness.
Sublingual: 120 mcg to 180 mcg as a single dose, administered under the tongue, one time. Maximum single dose: 180 mcg.
Instill 1 drop in the affected eye(s) every 6 to 8 hours as needed, not to exceed 4 drops per eye per day.
None Documented
None Documented
Terminal elimination half-life is 2.5 to 3.5 hours in healthy subjects, with prolonged half-life in patients with hepatic impairment (up to 5-7 hours) or renal impairment (up to 6-8 hours).
Approximately 2.5-3 hours (terminal) in adults; clinical context: duration of mydriasis may be shorter than half-life due to receptor binding.
Approximately 75% of the dose is excreted renally as unchanged drug, with the remainder eliminated via biliary/fecal routes (approximately 20%) and minor metabolic clearance.
Primarily renal (60-70% unchanged), with biliary/fecal elimination accounting for the remainder.
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist